Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Accord MedicinesSZSE:200028 82 PS Ratio is 0.09 as of Sep. 14, 2026, which is 67% below its 10-year median of 0.27. GuruFocus rates SZSE:200028 with a GF Score™ of 82/100 and a GF Value™ of HK$13.64 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 122 Medical Distribution companies, China National Accord Medicines ranks better than 74.59% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, China National Accord Medicines's share price is HK$12.07.
China National Accord Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$133.41. Hence, China National Accord Medicines's PS Ratio for today is 0.09.
Good Sign:
China National Accord Medicines Corp Ltd stock PS Ratio (=0.17) is close to 10-year low of 0.16.
The historical rank and industry rank for China National Accord Medicines's PS Ratio or its related term are showing as below:
SZSE:200028'
s PS Ratio Range Over the Past 10 Years
Min: 0.16 Med: 0.27 Max: 0.85
Current: 0.17
During the past 13 years, China National Accord Medicines's highest PS Ratio was 0.85. The lowest was 0.16. And the median was 0.27.
SZSE:200028's PS Ratio is ranked better than 74.59% of 122
companies
in the Medical Distribution industry
Industry Median: 0.435
vs SZSE:200028: 0.17
During the past 13 years, China National Accord Medicines's highest 3-Year average Revenue per Share Growth Rate was 174.70% per year. The lowest was -18.20% per year. And the median was 12.10% per year.
China National Accord Medicines (SZSE:200028) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
China National Accord Medicines PS Ratio Related Terms
China National Accord Medicines PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, China National Accord Medicines's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Accord Medicines PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's PS Ratio distribution charts can be found below:
* The bar in red indicates where China National Accord Medicines's PS Ratio falls into.
China National Accord Medicines PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
China National Accord Medicines's Share Price of today is HK$12.07. China National Accord Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$133.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
China National Accord Medicines (SZSE:200028) has a PS Ratio of 0.09 as of Sep. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China National Accord Medicines and its competitors. This is 67% below median its historical median of 0.27. Over the past decade, China National Accord Medicines' PS Ratio has ranged from 0.16 to 0.85. According to the industry distribution chart, China National Accord Medicines ranks #31 out of 122 companies in the Medical Distribution industry, placing it in the top 25.4%.
Is China National Accord Medicines' PS Ratio too high?
China National Accord Medicines' current PS Ratio of 0.09 is 67% below median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 0.85. The Medical Distribution industry median PS Ratio is 0.44. China National Accord Medicines' value of 0.09 is 79.3% below this industry median. Based on the distribution chart, China National Accord Medicines ranks #31 out of 122 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, China National Accord Medicines has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Accord Medicines' PS Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Accord Medicines ranks #31 out of 122 companies for PS Ratio. This puts China National Accord Medicines in the upper half of its industry. The industry median PS Ratio is 0.44. China National Accord Medicines' value of 0.09 is 79.3% below this benchmark. Historically, China National Accord Medicines' own PS Ratio has ranged from 0.16 to 0.85 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 0.44, China National Accord Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Distribution company?
The median PS Ratio among Medical Distribution companies is 0.44, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Accord Medicines's current PS Ratio of 0.09 is 79.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China National Accord Medicines and its competitors. For the Medical Distribution industry, the median PS Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Accord Medicines's current PS Ratio is 0.09, which is 67% below median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Accord Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Accord Medicines (SZSE:200028) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$13.64, compared to a current price of HK$12.07 — trading 11.5% below its estimated fair value. The current PS Ratio is 0.09, which is 67% below median its 10-year median of 0.27 and 79.3% below the Medical Distribution industry median of 0.44. China National Accord Medicines' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For China National Accord Medicines (SZSE:200028), the current PS Ratio is 0.09 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?
Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued.
The current stock price of HK$12.07 is trading 11.5% below its estimated GF Value™ of HK$13.64.
GuruFocus considers China National Accord Medicines to be Modestly Undervalued.
Key valuation signals for SZSE:200028:
PS Ratio: 0.09 (67% below median its 10-year median of 0.27)
GF Value™: HK$13.64 vs. price of HK$12.07 (11.5% below fair value)
Industry Position: 79.3% below the Medical Distribution median (#31 of 122)
No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score
Get the complete analysis for SZSE:200028
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:200028 has been successfully added to your 
